Investor Relations
Company Profile
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry.
"On June 24, 2026, LakeShore Biopharma Co., Ltd (the "Company") filed a Form 15 with the U.S. Securities and Exchange Commission (the “SEC”) to deregister its securities under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to terminate its reporting obligations under Section 15(d) of the Exchange Act.
The Company's previously filed reports remain available on the SEC’s EDGAR system at www.sec.gov. Information presented elsewhere on this website may relate to periods prior to the suspension of reporting and may not reflect the Company's current condition. The Company undertakes no obligation to update any such information except as required by applicable law."